Using a pilot-centric, qualitative drug risk assessment model to identify opportunities for implementing pharmacogenetics
Abstract
Risk assessment models are at the core of flight medicine, weighing both the impact of the flight environment on an aviator and the potential impact of medical events in aviators on flight operations. Pharmacogenetics is the application of a patient’s genetic information to reduce medication risk. Here, we use three medical conditions commonly encountered by the U.S. Air Force’s flight medicine community (asthma, diabetes, and hypertension) to demonstrate a framework for implementing occupationally relevant pharmacogenetics. We identified medications approved by the U.S. Food & Drug Administration for each condition, obtained adverse effects and frequencies, scored each adverse effect’s impact on work duties from 0 to 4 in increasing severity, and used control theory to stratify the medications by occupational risk. For those medications within 10% of the control limits, pharmacogenetic information was collected from PharmGKb.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 04, 2022
- Source ID
- 10.1186/s43094-022-00427-3
Entities
People
- Clesson E Turner
- Jacob Collie
- Jeffrey L. Kinard
- Richard R Chapleau